Have you ever heard of a condition where your immune system gets too overprotective and ends up causing more harm than good?

IGM Biosciences, Inc.’s IGMS share price has dipped by 6.85%, which has investors questioning if this is right time to buy.

The FDA has approved Uplizna (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease in adult patients.